Design Therapeutics (DSGN) Other Non-Current Liabilities (2020 - 2021)

Design Therapeutics (DSGN) reported Other Non-Current Liabilities of $11000.0 for Q3 2021, down 92.14% sequentially from $140000.0 in Q2 2021.

Design Therapeutics (DSGN) Other Non-Current Liabilities (2020 - 2021) Analysis & Trends

Design Therapeutics (DSGN) has 2 years of Other Non-Current Liabilities data on file, last reported at $11000.0 in Q3 2021.

For the quarter ending Q3 2021, Other Non-Current Liabilities changed N/A year-over-year to $11000.0; the trailing twelve-month figure through Sep 2021 stood at $11000.0 (changed N/A YoY), and the FY2020 full-year result was $145000.0, changed N/A from the prior year.
Other Non-Current Liabilities declined to $11000.0 in Q3 2021, from $140000.0 in the prior quarter.
In the past five years, Other Non-Current Liabilities ranged from a high of $145000.0 in Q4 2020 to a low of $11000.0 in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Design Therapeutics	714.48 Mn	491.66 Mn	-

Download Data